IL5 and eosinophilic granulomatosis with polyangiitis: As eosinophils play a central role in the pathogenesis of EGPA, anti-IL-5 therapies can specifically target the molecules for anti-eosinophilic treatments [10]. Anti-IL-5 therapies include the use of mepolizumab and benralizumab.